{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:55:04Z","timestamp":1793858104360,"version":"4.6.1"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":52,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1052"],"award-info":[{"award-number":["SFB 1052"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["209933838"],"award-info":[{"award-number":["209933838"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.peptides.2025.171404","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:46:37Z","timestamp":1744371997000},"page":"171404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery\u2606"],"prefix":"10.1016","volume":"188","author":[{"given":"Eva-Maria","family":"J\u00fclke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4560-8020","authenticated-orcid":false,"given":"Annette G.","family":"Beck-Sickinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2025.171404_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.peptides.2025.171404_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8227(11)70007-9","article-title":"The story of insulin discovery","volume":"93","author":"Karamitsos","year":"2011","journal-title":"Diabetes Res. Clin. Pr."},{"key":"10.1016\/j.peptides.2025.171404_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/0885066604265246","article-title":"Vasopressin: applications in clinical practice","volume":"19","author":"Dyke","year":"2004","journal-title":"J. Intensive Care. Med."},{"key":"10.1016\/j.peptides.2025.171404_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ajog.2023.06.041","article-title":"Oxytocin: physiology, pharmacology, and clinical application for labor management","volume":"230","author":"Hermesch","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.peptides.2025.171404_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.peptides.2025.171404_bib6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41589-022-01068-6","article-title":"Unconventional insulins from predators and pathogens","volume":"18","author":"Laugesen","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.peptides.2025.171404_bib7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1135\/cccc19671250","article-title":"Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-\u03b3-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin","volume":"32","author":"Zaoral","year":"1967","journal-title":"Collect. Czech. Chem. Commun."},{"key":"10.1016\/j.peptides.2025.171404_bib8","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.3390\/ijms23063068","article-title":"Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides","volume":"23","author":"Glava\u0161","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1021\/ja00897a025","article-title":"Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide","volume":"85","author":"Merrifield","year":"1963","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.peptides.2025.171404_bib10","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.bmc.2018.01.012","article-title":"Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics","volume":"26","author":"Erak","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3389\/fchem.2020.00571","article-title":"Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies","volume":"8","author":"Hoppenz","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/cbmi.4c00030","article-title":"Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine","volume":"2","author":"Shabsigh","year":"2024","journal-title":"Chem. Biomed. Imaging"},{"key":"10.1016\/j.peptides.2025.171404_bib13","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1210\/jc.2018-00665","article-title":"Macimorelin as a Diagnostic Test for Adult GH Deficiency","volume":"103","author":"Garcia","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2025.171404_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir Plus Ritonavir: First Approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40265-014-0295-4","article-title":"Oritavancin: first global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40265-014-0228-2","article-title":"Albiglutide: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-016-0501-5","article-title":"Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders","volume":"56","author":"Minder","year":"2017","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin","volume":"61","author":"Molina","year":"2022","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib19","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40265-014-0320-7","article-title":"Dulaglutide: first global approval","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib20","first-page":"142","article-title":"Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.peptides.2025.171404_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chest.2022.02.048","article-title":"The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs","volume":"162","author":"Bendicksen","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.peptides.2025.171404_bib22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1080\/14712598.2016.1238455","article-title":"Natpara for the treatment of hypoparathyroidism","volume":"16","author":"Marcucci","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.peptides.2025.171404_bib23","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","article-title":"Etelcalcetide: First Global Approval","volume":"76","author":"Blair","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-016-0558-3","article-title":"Elbasvir\/Grazoprevir: First Global Approval","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib25","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2967\/jnumed.116.186361","article-title":"Current Concepts in 68 Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies","volume":"58","author":"Bodei","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.peptides.2025.171404_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcp.2019.05.024","article-title":"Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide","volume":"166","author":"Bhattacharyya","year":"2019","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.ajem.2019.03.026","article-title":"Angiotensin II in septic shock","volume":"37","author":"Jadhav","year":"2019","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.peptides.2025.171404_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000519232","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial","volume":"94","author":"Cs\u00e1kv\u00e1ry","year":"2021","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.peptides.2025.171404_bib29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40265-017-0718-0","article-title":"Plecanatide: First Global Approval","volume":"77","author":"Al-Salama","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2017.1351295","article-title":"Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C","volume":"11","author":"Voaklander","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2025.171404_bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1756283X17734697","article-title":"Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation","volume":"10","author":"DeMicco","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.peptides.2025.171404_bib33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2025.171404_bib34","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s40265-019-01187-w","article-title":"Bremelanotide: First Approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib35","first-page":"38","article-title":"68GaGa-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging","volume":"13","author":"Hennrich","year":"2020","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.peptides.2025.171404_bib36","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2967\/jnumed.120.257808","article-title":"Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET","volume":"61","author":"Hope","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.peptides.2025.171404_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","article-title":"Setmelanotide: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib38","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/dom.14133","article-title":"Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome","volume":"22","author":"Haws","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2025.171404_bib39","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-021-01531-z","article-title":"Dasiglucagon: First Approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib40","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40265-021-01619-6","article-title":"Difelikefalin: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40265-021-01522-0","article-title":"Melphalan Flufenamide (Melflufen): First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib42","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s40265-021-01594-y","article-title":"Odevixibat: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib43","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40265-021-01488-z","article-title":"Voclosporin: First Approval","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib45","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40265-021-01623-w","article-title":"Vosoritide: First Approval","volume":"81","author":"Duggan","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40262-021-01059-1","article-title":"Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia","volume":"61","author":"Chan","year":"2022","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/RLI.0000000000001038","article-title":"Preclinical Safety Assessment of Gadopiclenol: A High-Relaxivity Macrocyclic Gadolinium-Based MRI Contrast Agent","volume":"59","author":"Gendron","year":"2024","journal-title":"Invest. Radio."},{"key":"10.1016\/j.peptides.2025.171404_bib48","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1080\/14656566.2023.2244427","article-title":"Terlipressin in the management of liver disease","volume":"24","author":"Scheinberg","year":"2023","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib49","article-title":"A Review of Terlipressin in Hepatorenal Syndrome: Targeting Endothelial Dysfunction and Subsequent Cardiovascular Adverse Events","author":"Bielawski","year":"2024","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.peptides.2025.171404_bib50","first-page":"822","article-title":"Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice","volume":"57","author":"Bradley","year":"2023","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib51","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2967\/jnumed.123.267271","article-title":"True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study","volume":"65","author":"Fleming","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.peptides.2025.171404_bib52","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s40265-023-01962-w","article-title":"Motixafortide: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib53","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: First Approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib54","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s40265-023-01922-4","article-title":"Sovateltide: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib55","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","article-title":"Trofinetide: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-023-01977-3","article-title":"Zilucoplan: First Approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib57","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40265-024-02023-6","article-title":"Danicopan: First Approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2025.171404_bib58","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40259-024-00670-5","article-title":"Insulin Icodec: First Approval","volume":"38","author":"Blair","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.peptides.2025.171404_bib59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41594-017-0011-7","article-title":"Structure and dynamics of GPCR signaling complexes","volume":"25","author":"Hilger","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.peptides.2025.171404_bib60","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tips.2010.06.003","article-title":"Peptide drugs to target G protein-coupled receptors","volume":"31","author":"Bellmann-Sickert","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib61","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2174\/156802610791384225","article-title":"Design and development of molecular imaging probes","volume":"10","author":"Chen","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"issue":"2","key":"10.1016\/j.peptides.2025.171404_bib62","first-page":"S23","article-title":"The Concise Guide to PHARMACOLOGY 2023\/24: G protein-coupled receptors","volume":"180","author":"Alexander","year":"2023","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/molecules26020430","article-title":"A Global Review on Short Peptides: Frontiers and Perspectives","volume":"26","author":"Apostolopoulos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.peptides.2025.171404_bib64","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The Discovery and Development of Liraglutide and Semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.peptides.2025.171404_bib65","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1021\/acs.jmedchem.1c00257","article-title":"Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans","volume":"64","author":"Kjeldsen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cbpa.2008.09.023","article-title":"Peptides as protein binding site mimetics","volume":"12","author":"Eichler","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.peptides.2025.171404_bib67","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.coph.2008.06.002","article-title":"Discovering and improving novel peptide therapeutics","volume":"8","author":"McGregor","year":"2008","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cbdd.12042","article-title":"Peptide scanning for studying structure-activity relationships in drug discovery","volume":"81","author":"Jamieson","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.peptides.2025.171404_bib69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0022-2836(90)90275-Q","article-title":"Strategy for analysing the co-operativity of intramolecular interactions in peptides and proteins","volume":"214","author":"Horovitz","year":"1990","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.peptides.2025.171404_bib70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/bs.apcsb.2016.06.002","article-title":"Recent Advances in Computational Models for the Study of Protein-Peptide Interactions","volume":"105","author":"Kilburg","year":"2016","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.peptides.2025.171404_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae275","article-title":"Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides","volume":"25","author":"Goles","year":"2024","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.peptides.2025.171404_bib72","article-title":"Peptides as Drug Candidates: Limitations and Recent Development Perspectives","volume":"8","author":"Haggag","year":"2018","journal-title":"Biomed. J. Sci. Tech. Res."},{"key":"10.1016\/j.peptides.2025.171404_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225546","article-title":"Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer","volume":"14","author":"Bottens","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.peptides.2025.171404_bib74","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","article-title":"Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2025.171404_bib75","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1021\/bi00420a015","article-title":"Role of peptide conformation in the rate and mechanism of deamidation of asparaginyl residues","volume":"27","author":"Lura","year":"1988","journal-title":"Biochemistry"},{"key":"10.1016\/j.peptides.2025.171404_bib76","doi-asserted-by":"crossref","first-page":"46809","DOI":"10.1021\/acsomega.2c05915","article-title":"Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide","volume":"7","author":"Wang","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.peptides.2025.171404_bib77","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1080\/00498254.2022.2119180","article-title":"Subcutaneous catabolism of peptide therapeutics: bioanalytical approaches and ADME considerations","volume":"52","author":"Esposito","year":"2022","journal-title":"Xenobiotica"},{"key":"10.1016\/j.peptides.2025.171404_bib78","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0378-5173(94)00172-2","article-title":"The stability of peptides in nasal enzymic systems","volume":"113","author":"Irwin","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134427","article-title":"Degradation and Stabilization of Peptide Hormones in Human Blood Specimens","volume":"10","author":"Yi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2025.171404_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3530","article-title":"Rational design of highly stabilized and selective adrenomedullin analogs","volume":"29","author":"J\u00fclke","year":"2023","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib82","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1021\/acs.jmedchem.6b00126","article-title":"Adrenomedullin 2.0: Adjusting Key Levers for Metabolic Stability","volume":"59","author":"Sch\u00f6nauer","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib83","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1021\/acschembio.0c00319","article-title":"Impact of the Endosomal Escape Activity of Cell-Penetrating Peptides on the Endocytic Pathway","volume":"15","author":"Kondow-McConaghy","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.peptides.2025.171404_bib84","doi-asserted-by":"crossref","DOI":"10.1021\/acsptsci.4c00503","article-title":"Comparison of protocols to test peptide stability in blood plasma and cell culture supernatants","author":"Kohler","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/psc.2948","article-title":"Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates","volume":"23","author":"Grob","year":"2017","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1232","article-title":"Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors","volume":"8","author":"Tang","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.peptides.2025.171404_bib87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1399-3011.2004.00213.x","article-title":"Solid-phase synthesis and characterization of N-methyl-rich peptides","volume":"65","author":"Teixid\u00f3","year":"2005","journal-title":"J. Pept. Res."},{"key":"10.1016\/j.peptides.2025.171404_bib88","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/jm101016w","article-title":"Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV","volume":"54","author":"Zhang","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib89","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/anie.201205674","article-title":"N-methylation of peptides and proteins: an important element for modulating biological functions","volume":"52","author":"Chatterjee","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.peptides.2025.171404_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106892","article-title":"Backbone N-methylation of peptides: Advances in synthesis and applications in pharmaceutical drug development","volume":"141","author":"Li","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib91","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cbdv.200590039","article-title":"The proteolytic stability of \u2018designed\u2019 beta-peptides containing alpha-peptide-bond mimics and of mixed alpha,beta-peptides: application to the construction of MHC-binding peptides","volume":"2","author":"Hook","year":"2005","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.peptides.2025.171404_bib92","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/psc.1434","article-title":"Synthesis of anticancer heptapeptides containing a unique lipophilic \u03b2(2,2) -amino acid building block","volume":"18","author":"T\u00f8rfoss","year":"2012","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib93","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1021\/acsmedchemlett.3c00037","article-title":"Beyond 20 in the 21st Century: Prospects and Challenges of Non-canonical Amino Acids in Peptide Drug Discovery","volume":"14","author":"Hickey","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.peptides.2025.171404_bib94","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1039\/D3SC05738K","article-title":"Biocompatible strategies for peptide macrocyclisation","volume":"15","author":"He","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib95","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1039\/D1OB00411E","article-title":"Approaches for peptide and protein cyclisation","volume":"19","author":"Hayes","year":"2021","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib96","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature22394","article-title":"Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.peptides.2025.171404_bib97","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41467-022-28510-6","article-title":"Structural basis of neuropeptide Y signaling through Y1 receptor","volume":"13","author":"Park","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2025.171404_bib98","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1124\/mol.119.115915","article-title":"Understanding Peptide Binding in Class A G Protein-Coupled Receptors","volume":"96","author":"Tikhonova","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.regpep.2012.12.012","article-title":"The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs","volume":"181","author":"Simonsen","year":"2013","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2025.171404_bib100","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/bm500246w","article-title":"PEG\u2013Peptide Conjugates","volume":"15","author":"Hamley","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.peptides.2025.171404_bib101","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1002\/ajh.26875","article-title":"Complement-targeted therapeutics: An emerging field enabled by academic drug discovery","volume":"98","author":"Lamers","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.peptides.2025.171404_bib102","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1006\/jmbi.2000.4158","article-title":"Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin","volume":"303","author":"Bhattacharya","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.peptides.2025.171404_bib103","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/1869","article-title":"Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites","volume":"5","author":"Curry","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.peptides.2025.171404_bib104","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2174\/1381612821666150302113710","article-title":"Studies on drug-human serum albumin binding: the current state of the matter","volume":"21","author":"Zhivkova","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.peptides.2025.171404_bib105","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2165\/00003495-200464220-00008","article-title":"Insulin Detemir","volume":"64","author":"Chapman","year":"2004","journal-title":"Drugs"},{"issue":"Pt 3","key":"10.1016\/j.peptides.2025.171404_bib106","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj3120725","article-title":"Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo","volume":"312","author":"Kurtzhals","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.peptides.2025.171404_bib107","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1023\/B:PHAM.0000036926.54824.37","article-title":"The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin","volume":"21","author":"Havelund","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.peptides.2025.171404_bib108","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2025.171404_bib109","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib110","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1517\/14712598.2010.481281","article-title":"Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes","volume":"10","author":"St Onge","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.peptides.2025.171404_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116464","article-title":"Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM)","volume":"272","author":"Shao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib112","first-page":"923","article-title":"The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection","volume":"9","author":"Jin","year":"2015","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.peptides.2025.171404_bib113","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1046\/j.1471-4159.1998.70051781.x","article-title":"CNS drug design based on principles of blood-brain barrier transport","volume":"70","author":"Pardridge","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.peptides.2025.171404_bib114","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/glia.20725","article-title":"Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection","volume":"56","author":"Ronaldson","year":"2008","journal-title":"Glia"},{"key":"10.1016\/j.peptides.2025.171404_bib115","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s00429-021-02341-5","article-title":"B3Pdb: an archive of blood-brain barrier-penetrating peptides","volume":"226","author":"Kumar","year":"2021","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.peptides.2025.171404_bib116","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1039\/C6CS00076B","article-title":"Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery","volume":"45","author":"Oller-Salvia","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.peptides.2025.171404_bib117","doi-asserted-by":"crossref","first-page":"OT1-06-01","DOI":"10.1158\/1538-7445.SABCS18-OT1-06-01","volume":"79","author":"Kumthekar","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.peptides.2025.171404_bib118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molmet.2019.11.009","article-title":"NPY1R-targeted peptide-mediated delivery of a dual PPAR\u03b1\/\u03b3 agonist to adipocytes enhances adipogenesis and prevents diabetes progression","volume":"31","author":"Wittrisch","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2025.171404_bib119","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bjo.88.1.25","article-title":"The efficacy and safety of topical polymyxin B, neomycin and gramicidin for treatment of presumed bacterial corneal ulceration","volume":"88","author":"Bosscha","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.peptides.2025.171404_bib120","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The Current State of Peptide Drug Discovery: Back to the Future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib121","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/annonc\/mdj044","article-title":"Patients\u2019 preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer","volume":"17","author":"Fallowfield","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.peptides.2025.171404_bib122","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1021\/acs.chemrev.6b00838","article-title":"Orally Absorbed Cyclic Peptides","volume":"117","author":"Nielsen","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.peptides.2025.171404_bib123","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1021\/jm201634q","article-title":"Predicting and improving the membrane permeability of peptidic small molecules","volume":"55","author":"Rafi","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2025.171404_bib124","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.peptides.2025.171404_bib125","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.peptides.2025.171404_bib126","first-page":"346","article-title":"Infectious risks of chronic pain treatments: injection therapy, surgical implants, and intradiscal techniques","volume":"31","author":"Rathmell","year":"2006","journal-title":"Reg. Anesth. Pain. Med."},{"key":"10.1016\/j.peptides.2025.171404_bib127","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.peptides.2025.171404_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109706","article-title":"Protein and peptide delivery to lungs by using advanced targeted drug delivery","volume":"351","author":"Chellappan","year":"2022","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.peptides.2025.171404_bib129","article-title":"Transdermal delivery of peptide and protein drugs: Strategies, advantages and disadvantages","volume":"60","author":"Long","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.peptides.2025.171404_bib130","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1002\/jps.21277","article-title":"Proteins and peptides: strategies for delivery to and across the skin","volume":"97","author":"Benson","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib131","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jconrel.2012.05.030","article-title":"The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin","volume":"161","author":"Liu","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.peptides.2025.171404_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100427","article-title":"Pulmonary and cardiovascular safety of inhaled insulin in routine practice: The Exubera Large Simple Trial (VOLUME)","volume":"18","author":"Gatto","year":"2020","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.peptides.2025.171404_bib133","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.peptides.2025.171404_bib134","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.arcped.2018.11.002","article-title":"Parental acceptance of an intranasal vaccine: Example of influenza vaccine","volume":"26","author":"Marien","year":"2019","journal-title":"Arch. Pedia"},{"key":"10.1016\/j.peptides.2025.171404_bib135","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.peptides.2025.171404_bib136","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1208\/s12249-015-0294-0","article-title":"Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles","volume":"16","author":"Sharma","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.peptides.2025.171404_bib137","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1745-459X.1999.tb00129.x","article-title":"Patient Prefernce And Sensory Comparison of Nasal Spray Allergy Medication","volume":"14","author":"Gerson","year":"1999","journal-title":"J. Sens. Stud."},{"key":"10.1016\/j.peptides.2025.171404_bib138","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.peptides.2025.171404_bib139","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.044","article-title":"Stimuli-responsive In situ gelling system for nose-to-brain drug delivery","volume":"327","author":"Agrawal","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.peptides.2025.171404_bib140","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1208\/s12249-017-0844-8","article-title":"Development and Evaluation of pH-Responsive Cyclodextrin-Based in situ Gel of Paliperidone for Intranasal Delivery","volume":"19","author":"Sherje","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.peptides.2025.171404_bib141","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1039\/C5SM02710A","article-title":"Recent trends in pH\/thermo-responsive self-assembling hydrogels: from polyions to peptide-based polymeric gelators","volume":"12","author":"Chassenieux","year":"2016","journal-title":"Soft Matter"},{"key":"10.1016\/j.peptides.2025.171404_bib142","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1021\/ja00042a001","article-title":"Structural characterization of the.beta.-bend ribbon spiral: crystallographic analysis of two long (L-Pro-Aib)n sequential peptides","volume":"114","author":"Di Blasio","year":"1992","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.peptides.2025.171404_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib144","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.4103\/1673-5374.241458","article-title":"Nose-to-brain drug delivery approach: A key to easily accessing the brain for the treatment of Alzheimer\u2019s disease","volume":"13","author":"Alexander","year":"2018","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.peptides.2025.171404_bib145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0973-8398.45032","article-title":"Bioavailability of intranasal drug delivery system","volume":"2","author":"Bhise","year":"2014","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib146","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib147","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.peptides.2025.171404_bib148","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.peptides.2025.171404_bib149","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib150","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.addr.2007.10.008","article-title":"Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers","volume":"60","author":"Torchilin","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.peptides.2025.171404_bib151","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00688493","article-title":"Uptake of exogenous proteins in mouse olfactory cells","volume":"19","author":"Kristensson","year":"1971","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.peptides.2025.171404_bib152","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/1061186X.2013.876644","article-title":"Intranasal therapeutic strategies for management of Alzheimer\u2019s disease","volume":"22","author":"Sood","year":"2014","journal-title":"J. Drug Target"},{"key":"10.1016\/j.peptides.2025.171404_bib153","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41598-019-39191-5","article-title":"Distribution of insulin in trigeminal nerve and brain after intranasal administration","volume":"9","author":"Lochhead","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.peptides.2025.171404_bib154","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/rep.1.00278","article-title":"Counter-current transfer in reproductive biology","volume":"129","author":"Einer-Jensen","year":"2005","journal-title":"Reproduction"},{"key":"10.1016\/j.peptides.2025.171404_bib155","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3390\/pharmaceutics14091870","article-title":"Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols","volume":"14","author":"Alabsi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.peptides.2025.171404_bib156","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41380-020-00864-7","article-title":"Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research","volume":"26","author":"Quintana","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.peptides.2025.171404_bib157","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4155\/tde-2018-0002","article-title":"Evidence for intranasal oxytocin delivery to the brain: recent advances and future perspectives","volume":"9","author":"Quintana","year":"2018","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.peptides.2025.171404_bib158","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fendo.2015.00090","article-title":"A Role for Oxytocin in the Etiology and Treatment of Schizophrenia","volume":"6","author":"Rich","year":"2015","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.peptides.2025.171404_bib159","series-title":"Behavioral Pharmacology of Neuropeptides: Oxytocin","first-page":"449","article-title":"Oxytocin and Autism Spectrum Disorders","author":"Yamasue","year":"2018"},{"key":"10.1016\/j.peptides.2025.171404_bib160","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.146","article-title":"Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism","volume":"5","author":"Auyeung","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.peptides.2025.171404_bib161","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41386-018-0258-7","article-title":"Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: a randomized trial","volume":"44","author":"Kruppa","year":"2019","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.peptides.2025.171404_bib162","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-020-0313-1","article-title":"Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up","volume":"11","author":"Bernaerts","year":"2020","journal-title":"Mol. Autism"},{"key":"10.1016\/j.peptides.2025.171404_bib163","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.euroneuro.2020.11.014","article-title":"Changes in endogenous oxytocin levels after intranasal oxytocin treatment in adult men with autism: An exploratory study with long-term follow-up","volume":"43","author":"Alaerts","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.peptides.2025.171404_bib164","article-title":"The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report","volume":"4","author":"Lee","year":"2019","journal-title":"J. Psychiatr. Brain Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib165","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2017.01.008","article-title":"A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia","volume":"185","author":"Jarskog","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.peptides.2025.171404_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223629","article-title":"Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development","volume":"11","author":"Bose","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.peptides.2025.171404_bib167","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/scan\/nsv116","article-title":"Effects of intranasal oxytocin on amygdala reactivity to emotional faces in recently trauma-exposed individuals","volume":"11","author":"Frijling","year":"2016","journal-title":"Soc. Cogn. Affect. Neurosci."},{"key":"10.1016\/j.peptides.2025.171404_bib168","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1210\/clinem\/dgad015","article-title":"Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial","volume":"108","author":"Roof","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2025.171404_bib169","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ijnp\/pyx109","article-title":"A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder","volume":"21","author":"Sayed","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.peptides.2025.171404_bib170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/157488607781668891","article-title":"J.P. N\u00f8rgaard. Desmopressin 30 years in clinical use: a safety review","volume":"2","author":"Vande Walle","year":"2007","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.peptides.2025.171404_bib171","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1507\/endocrj.EJ14-0368","article-title":"Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus","volume":"62","author":"Kataoka","year":"2015","journal-title":"Endocr. J."},{"key":"10.1016\/j.peptides.2025.171404_bib172","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00228-022-03297-z","article-title":"Desmopressin therapy in children and adults: pharmacological considerations and clinical implications","volume":"78","author":"Chin","year":"2022","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib173","doi-asserted-by":"crossref","first-page":"8","DOI":"10.18787\/jr.2024.00007","article-title":"Does Desmopressin Reduce Intraoperative Bleeding in Patients Who Undergo Nasal Surgery? A Systematic Review and Meta-Analysis","volume":"31","author":"Kim","year":"2024","journal-title":"J. Rhinol."},{"key":"10.1016\/j.peptides.2025.171404_bib174","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7356","article-title":"A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism","volume":"11","author":"Parker","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.peptides.2025.171404_bib175","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/ejhg.2016.109","article-title":"Is there an effect of intranasal insulin on development and behaviour in Phelan-McDermid syndrome? A randomized, double-blind, placebo-controlled trial","volume":"24","author":"Zwanenburg","year":"2016","journal-title":"Eur. J. Hum. Genet"},{"key":"10.1016\/j.peptides.2025.171404_bib176","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bdi.12006","article-title":"A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder","volume":"14","author":"McIntyre","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.peptides.2025.171404_bib177","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0b013e31828701d0","article-title":"No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia","volume":"33","author":"Fan","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.peptides.2025.171404_bib178","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jad.2016.12.006","article-title":"A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder","volume":"210","author":"Cha","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.peptides.2025.171404_bib179","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.psyneuen.2008.08.002","article-title":"Intranasal insulin attenuates the hypothalamic-pituitary-adrenal axis response to psychosocial stress","volume":"33","author":"Bohringer","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.peptides.2025.171404_bib180","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41386-019-0593-3","article-title":"Effects of intranasal insulin as an enhancer of fear extinction: a randomized, double-blind, placebo-controlled experimental study","volume":"45","author":"Ferreira de S\u00e1","year":"2020","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.peptides.2025.171404_bib181","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","article-title":"Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype","volume":"27","author":"Reger","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.peptides.2025.171404_bib182","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.peptides.2025.171404_bib183","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.peptides.2025.171404_bib184","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JAD-2011-110149","article-title":"A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer\u2019s disease","volume":"26","author":"Stein","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.peptides.2025.171404_bib185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214364","article-title":"Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study","volume":"14","author":"Novak","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2025.171404_bib186","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","article-title":"A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.peptides.2025.171404_bib187","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41398-024-03118-0","article-title":"Davunetide sex-dependently boosts memory in prodromal Alzheimer\u2019s disease","volume":"14","author":"Gozes","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.peptides.2025.171404_bib188","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s11095-016-1896-2","article-title":"Visualization and Quantification of Nasal and Olfactory Deposition in a Sectional Adult Nasal Airway Cast","volume":"33","author":"Xi","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.peptides.2025.171404_bib189","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.MLG.0000199741.08517.99","article-title":"Breath actuated device improves delivery to target sites beyond the nasal valve","volume":"116","author":"Djupesland","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.peptides.2025.171404_bib190","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/17425247.2018.1517742","article-title":"Overview of intranasally delivered peptides: key considerations for pharmaceutical development","volume":"15","author":"Al Bakri","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.peptides.2025.171404_bib191","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","article-title":"Progress in brain targeting drug delivery system by nasal route","volume":"268","author":"Khan","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.peptides.2025.171404_bib192","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.626882","article-title":"Design and Application in Delivery System of Intranasal Antidepressants","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.peptides.2025.171404_bib193","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jps.20480","article-title":"Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting","volume":"95","author":"Vyas","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.peptides.2025.171404_bib194","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357011775145","article-title":"The biopharmaceutical aspects of nasal mucoadhesive drug delivery","volume":"53","author":"Ugwoke","year":"2001","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.peptides.2025.171404_bib195","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1016\/j.biomaterials.2013.08.036","article-title":"Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles","volume":"34","author":"Kanazawa","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.peptides.2025.171404_bib196","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","article-title":"Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration","volume":"134","author":"Gartziandia","year":"2015","journal-title":"Colloids Surf. B. Biointerfaces"},{"key":"10.1016\/j.peptides.2025.171404_bib197","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.1021\/acsnano.5b01326","article-title":"Surface Functionalization of Nanoparticles with Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake","volume":"9","author":"Pelaz","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.peptides.2025.171404_bib198","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","article-title":"Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson\u2019s disease following intranasal administration","volume":"151","author":"Wen","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.peptides.2025.171404_bib199","article-title":"TAT modification facilitates nose-to-brain transport of intact mPEG-PDLLA micelles: Evidence from aggregation-caused quenching probes","volume":"19","author":"Ahmad","year":"2020","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.peptides.2025.171404_bib200","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1039\/C6NR07581A","article-title":"Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles","volume":"9","author":"Ahmad","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.peptides.2025.171404_bib201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(94)00158-2","article-title":"Effects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats","volume":"113","author":"Morimoto","year":"1995","journal-title":"Int. J. Pharm."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978125000658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978125000658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:41:47Z","timestamp":1777527707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978125000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":201,"alternative-id":["S0196978125000658"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2025.171404","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery\u2606","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2025.171404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"171404"}}